Shattuck Labs, Inc. is a biotechnology company focused on developing innovative therapies for cancer and other serious diseases. The company utilizes its proprietary PureT™ platform to create advanced bispecific and multi-specific immune-oncology therapeutics that aim to enhance the body's immune response against tumors. Through its research and development efforts, Shattuck Labs seeks to address unmet medical needs and improve treatment outcomes for patients by advancing novel treatments that harness the power of the immune system in a targeted manner. Read More
AUSTIN, TX and DURHAM, NC, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that Company management will participate in a panel discussion focused on key takeaways from the United European Gastroenterology Week (UEGW) Conference 2025. The session will be moderated by covering analysts Martin Fan, Ph.D. and David Nierengarten, Ph.D., and will feature KOL Marla Dubinsky, M.D., Director of the Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center at Mount Sinai Health System.
Corporate insiders, often privy to the most granular details of their companies' health and future prospects, have been sending a clear signal to the market over the past 12-18 months: caution. A significant surge in insider selling, particularly pronounced in 2025, has overshadowed buying activity, pushing the U.S. market
After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
— Aggregate net proceeds from private placement expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease —
– SL-325 is a potentially first-in-class DR3 antagonist antibody being developed for the treatment of Inflammatory Bowel Disease (IBD) and other inflammatory and immune-mediated diseases –
– Submitted Investigational New Drug (IND) application to evaluate SL-325 in a Phase 1 clinical trial in healthy volunteers; clearance expected in Q3 2025 –
Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top gainers and losers in today's session.
Stay up-to-date with the latest market trends in the middle of the day on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
– Aggregate net proceeds expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease (IBD) and potentially another autoimmune disease –
AUSTIN, TX and DURHAM, NC, July 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that company management will participate in a DR3/TL1A focused panel discussion and participate in one-on-one meetings at the Leerink Partners Therapeutics Forum: I&I and Metabolism on July 8–9, 2025 in Boston, MA.
Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session.
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
